The First International HPV Vaccine Information Clearinghouse
OpEdNews
By K.L. Carlson
August 18, 2010
According to FDA documents, HPV infections do not lead to cervical cancer. “Most infections by HPV are short-lived and not associated with cervical cancer,” states an FDA news release dated March 31, 2003. According to another FDA document, the Gardasil vaccine has been found to increase the risk of developing precancerous lesions by more than 44 percent in young women already infected with the HP virus strains used in the vaccine.
Roche.com
Basel, 11 April 2007
Roche to develop and commercialize products from Transgene’s programme.
Roche and Transgene announced today that they have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from Transgene’s therapeutic vaccine program against Human Papilloma Virus-mediated diseases.
HPV 2010 Conference
Montreal Canada
July 3-8, 2010
Conclusion: Our data do not provide sufficient evidence to modify existing 3-dose schedules, but suggest that fewer than three doses may provide a high degree of protection against HPV-16/18 infection. Systematic evaluation of one- and two-dose schedules is justified.
The Hindu News
August 9, 2010
Aarti Dhar
Information on the demonstration project and licensing of two vaccines to prevent cervical cancer has been exempted from public disclosure under Section 8 of the Right to Information Act, 2005.
PubMed.gov
Clin Vaccine Immunol. 2010 Jul 28. [Epub ahead of print]
Human papillomavirus (HPV) 58 exists in a relatively high prevalence in certain parts of the world including East Asia. This study examined T-cell response to HPV 58 L1, E6 and E7 peptides among women with cleared infection, cervical intraepithelial neoplasia (CIN) grade 2 and 3, and invasive cervical cancer (ICC).
